News

New report calling for the Biomedical Catalyst scheme to be continued


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

New report calling for the Biomedical Catalyst scheme to be continued in the interest of the nation’s health and wealth

 

Date: 11/08/2015


New report calling for the Biomedical Catalyst scheme to be continued in the interest of the nation’s health and wealth.

Today the UK BioIndustry Association (BIA) publishes a new report, The Biomedical Catalyst, making the case to continue.

Published following the announcement of the last round of the current Biomedical Catalyst (BMC) funding allocation, the report gives a retrospective of the current scheme and showcases ten case studies from companies who have been recipients of BMC funding.

To date the BMC scheme has awarded over £250 million to accelerate medical research. Over 180 business-led projects have been supported with funds worth over £130 million and with a total project value of over £240 million. This means that over £100m of additional private capital, in the form of matched funding, has been leveraged as a condition of the Biomedical Catalyst awards. Furthermore, beyond the Biomedical Catalyst awards, post-award funded companies and academics have realised in excess of a further billion pounds in the form of additional private finance, grant funding, via licensing or acquisition.

For more click here

Source: One nucleus

© Catalyst Innovation Portal 2019